Institutional investors, including Capital Research Global Investors and Geode Capital Management, increased their stake in Alnylam Pharmaceuticals, requiring SEC filings.
1 report, 1 independent
Updated Jun 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Institutional investors, including Capital Research Global Investors and Geode Capital Management, increased their stake in Alnylam Pharmaceuticals, requiring SEC filings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- GT Biopharma filed with the SEC regarding institutional investment, and its stock traded on the Nasdaq exchange.
- Pfizer filed with the SEC on May 27, 2026, regarding institutional share holdings and active buying/selling of stock.
- The SEC is tracking 13F filings submitted by institutional investors, involving Omnicom Group.
- Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.